Non-alcoholic Fatty Liver Disease Clinical Trial
Official title:
Unravelling the Pathogenetic Mechanisms of Fructose in Comparison to Glucose Consumption as Multiple Hit in the Pathogenesis and Progression of Non-alcoholic Fatty Liver Disease (NAFLD) - an Exploratory Trial
Non-alcoholic fatty liver disease (NAFLD) comprises a spectrum ranging from simple fatty liver over steatohepatitis (NASH) to liver cirrhosis and cancer (HCC) and is a major and increasing health problem affecting nearly 40% of the general population. Moreover, NAFLD is an important risk factor for progression of diabetes and atherosclerosis. However, the pathomechanisms determining disease progression are poorly understood. The overall aim of this project is to test the central hypothesis that excessive fructose consumption provides a multiple metabolic hit in the pathogenesis and progression of NAFLD/NASH by impairment of hepatic lipid homeostasis and mitochondrial function resulting in hepatic lipotoxicity with inflammasome activation and disturbed interorgan cross-talk among insulin sensitive tissues.
To achieve these goals we will address the following specific hypotheses that
- Fructose-induced changes in lipid composition of hepatocellular stores determine
lipotoxicity which may be associated with abnormalities in mitochondrial function,
energy homeostasis, inflammasome activation and cellular injury in progression to NASH,
effects which will be compared to glucose
- Non-invasive characterization of fructose (compared to glucose)-induced lipotoxic
hepatic and extrahepatic metabolic risk profiles (lipid composition and energy
metabolism) obtained by magnetic resonance spectroscopy (MRS) will identify patients
with NASH
- Severity of fructose (compared to glucose)-induced lipotoxic lipid and adenosine
triphosphate (ATP) derangements (identified by MRS) critically determines the degree of
insulin resistance and abnormalities in hepatic glucose and lipid metabolism
- Compensatory hyperinsulinemia, secondary to skeletal muscle insulin resistance, may be a
primary mechanism of hepatic lipotoxicity and progression to NASH
- Gender differences in the hepatic and systemic metabolic response to fructose are
mediated by the impact of female sex hormones and their nuclear receptors on hepatic
lipid metabolism, mitochondrial function and inflammasome activation.
- Age differences in the hepatic and systemic metabolic response to fructose are mediated
by the impact of age related alterations on hepatic lipid metabolism and mitochondrial
function.
These key hypotheses will be addressed by a translational research consortium including
hepatologists, radiologists, physicists, endocrinologists and specialist in gender medicine
allowing an integrated mechanistic approach to NAFLD. The strength of the current proposal
comes directly from bridging basic science and clinical perspectives of different disciplines
involved in the management of NAFLD, including cutting edge non-invasive technologies such as
high field MRS metabolic profiling ('virtual metabolic liver biopsy') and mechanistic in
vitro experiments. This project will provide novel mechanistic insights in the role of
fructose as emerging hepatic 'toxin' in the pathogenesis and progression of NASH, as
increasing health problem in Western society. Moreover, this study will clarify the impact of
sex and gender on fructose-induced alterations in hepatic and systemic metabolism, providing
a rational and scientific basis for future dietary interventions and regulatory actions.
;
Status | Clinical Trial | Phase | |
---|---|---|---|
Recruiting |
NCT05480696 -
Soluble Fibre Supplementation in NAFLD
|
Phase 1 | |
Active, not recruiting |
NCT02500147 -
Metformin for Ectopic Fat Deposition and Metabolic Markers in Polycystic Ovary Syndrome (PCOS)
|
Phase 4 | |
Completed |
NCT04671186 -
Role of Probiotics in Treatment of Pediatric NAFLD Patients by Assessing With Fibroscan
|
N/A | |
Recruiting |
NCT05979779 -
Ph 2 Study of the Safety and Efficacy of Three HU6 Dose Levels and Placebo in Nonalcoholic Steatohepatitis
|
Phase 2 | |
Recruiting |
NCT05462353 -
Study to Evaluate the Safety, Tolerability, and Efficacy of ASC41 Tablets in Adult Patients With NASH
|
Phase 2 | |
Completed |
NCT05006885 -
ALT-801 in Diabetic and Non-Diabetic Overweight and Obese Subjects With Non-alcoholic Fatty Liver Disease (NAFLD)
|
Phase 1 | |
Completed |
NCT04117802 -
Effects of Maple Syrup on Gut Microbiota Diversity and Metabolic Syndrome
|
N/A | |
Recruiting |
NCT04365855 -
The Olmsted NAFLD Epidemiology Study (TONES)
|
N/A | |
Recruiting |
NCT05618626 -
Prevention of NAFLD and CVD Through Lifestyle Intervention
|
N/A | |
Completed |
NCT03256526 -
6-week Safety and PD Study in Adults With NAFLD
|
Phase 2 | |
Enrolling by invitation |
NCT06152991 -
Clinical Trial Assessing Godex Carnitine Orotate Complex in Nonalcoholic Fatty Liver Disease Patients for Efficacy
|
Phase 3 | |
Completed |
NCT03681457 -
Evaluation of the Pharmacokinetics of Tropifexor in Subjects With Mild, Moderate, or Severe Hepatic Impairment Compared to Healthy Control Subjects
|
Phase 1 | |
Completed |
NCT06244550 -
Clinical Trials Using HepatoKeeper Herbal Essentials to Treat Non-alcoholic Fatty Liver Disease and Metabolic Factors
|
N/A | |
Not yet recruiting |
NCT05120557 -
Point-of-care Ultrasound Screening and Assessment of Chronic Liver Diseases and NASH
|
N/A | |
Completed |
NCT03060694 -
Screening Diabetes Patients for NAFLD With Controlled Attenuation Parameter and Liver Stiffness Measurements
|
||
Completed |
NCT02526732 -
Hepatic Inflammation and Physical Performance in Patients With NASH
|
N/A | |
Recruiting |
NCT01988441 -
The Influence of Autophagy on Fatty Liver
|
||
Recruiting |
NCT01680003 -
Hepar-P Study to Evaluate the Safety and Efficacy of a Standardised Extract of Phyllanthus Niruri for the Treatment of Non-alcoholic Fatty Liver Disease
|
Phase 2 | |
Completed |
NCT01712711 -
Helicobacter Pylori Eradication in Diabetic Subjects With Non-alcoholic Fatty Liver Disease
|
Phase 2 | |
Recruiting |
NCT00941642 -
Placebo Controlled Study Using Lovaza as Treatment for Non-Alcoholic Fatty Liver Disease
|
Phase 4 |